Extensive research of BRCA1 and BRCA2 mutations has led to well-defined breast and ovarian cancer risks in individuals with HBOC. Previous studies have reported additional cancers associated with BRCA mutations; however, the type of cancer, magnitude of risk, and differences between sexes remains to be clarified. Ultimately, a consensus of additional cancer risks can aid in better recommendations for genetic testing and more effective screening and prevention guidelines.
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Introduction BRCA1 and BRCA2 tumor suppressor genes repair DNA damage to prevent tumor development. Mutations in these genes predispose an individual to malignancy. The types of cancers associated with mutations in BRCA1 and BRCA2 have been studied continuously since their discovery in 1994 and 1995 respectively (Miki et al., 1994 & Wooster et al., 1995 .
Individuals with BRCA1 and BRCA2 mutations have a significantly increased lifetime risk for developing breast and ovarian cancer, as high as 84% and 39% respectively (Antoniou et al., 2003; Chen et al., 2006; Easton et al., 1995; Ford et al., 1998) .
While the association of BRCA1 and BRCA2 mutations with breast and ovarian cancer risks is well-defined, the potential association of these mutations with other cancers is inconsistent. Prior studies have included families either at high risk for a BRCA mutation or combined BRCA1 and BRCA2 mutations carriers for analysis due to small numbers of individuals with BRCA mutations (Bermejo & Hemminki, 2004; Noh et al., 2012) . These studies reported an increased incidence of cancers, other than breast and ovarian, in mutation carriers;
however, these reports did not differentiate between BRCA1 and BRCA2 mutation carriers.
Studies have been able to focus on BRCA1 or BRCA2 mutation carriers separately;
however, the number of participants varies, with few studies containing more than 1000 mutation carriers. Ford et al (1994) found an increased risk for both sexes, while Thompson and Easton (2000) found an increased risk only in women and Moran et al (2012) reported BRCA1 mutations are not associated with an increased risk for other cancers. BRCA1 mutation carriers have a significantly increased risk of pancreatic, prostate, and colorectal cancer as reported in multiple studies (Brose et al, 2002; Ford et al, 1994; Iqbal et al., 2012; Phelan et al., 2014; Thompson et al., 2002) . BRCA1 mutations have been linked to increases in cervical, esophagus, liver, stomach, and uterine cancers; however, the increased risks were inconsistent and ranged from one to four fold (Brose et al, 2002; Ford et al, 1994; Moran et al, 2012; Thompson et al., 2002) . Known environmental risk factors associated with these cancers were not typically reported in these studies.
The Breast Cancer Linkage Consortium (BCLC) reported BRCA2 mutations were associated with an increased cancer risk in both sexes (1999), while van Asperen found a significantly increased risk for men only (2005) . The most commonly reported cancers with BRCA2 mutations include pancreas, prostate, and melanoma (BCLC, 1999; Easton et al., 1997; Moran et al., 2012; Tai et al., 2007; van Asperen et al., 2005) . Additional cancers reported in the BRCA2 spectrum include bone, buccal cavity and pharynx, esophagus, gallbladder and bile duct, laryngeal, ocular, male breast cancer, and stomach, although inconsistently across multiple studies. (BCLC, 1999; Easton et al., 1997; Moran et al., 2012; Tai et al., 2007; van Asperen et al., 2005) . Environmental risk factors for these cancers were not regularly reported in these studies.
The purpose of this study was to determine if cancers, other than breast and ovarian, were detected more often in BRCA mutation carriers than in the general population. The limited number of studies and variable results indicate a need for further research on the occurrence of non breast or ovarian cancers that are associated with BRCA1 and BRCA2 mutations.
Ultimately, a consensus of additional cancer risk may aid in better recognition of at-risk families where genetic testing may be warranted and in more effective screening guidelines for the types of cancer these families are at risk to develop.
Methods

Study Population
This study was approved by the MD Anderson Cancer Center Institutional Review Individuals with two BRCA mutations, either deleterious or suspected deleterious, in the same gene were included in the analysis. Individuals with mutations in both the BRCA1 and BRCA2 genes, or with both a BRCA mutation and another known cancer-predisposing mutation or genetic condition were excluded from this analysis.
Statistical Methods
Cancer cases were counted for the total sample as well as for BRCA1 and BRCA2 mutation carriers separately. The earliest age at diagnosis was used in the analysis for individuals that developed the same cancer more than once in their lifetime. Most cancers were analyzed independently. Similar or related cancers were grouped together for analysis. For example glioma, astrocytoma, and neuroblastoma were grouped into brain/central nervous system cancers. Ovarian cancer was also defined to include primary peritoneal and fallopian tube cancers. Within each cancer, or group of cancers, the data were stratified by sex and ethnicity.
We compared cancer incidence in our sample with the United States Cancer Statistics:
1999-2010 Incidence and Morality Web-based Report (USCS) from the Centers of Disease
Control and Prevention (CDC). Data from the USCS report combines the CDC's National
Program of Cancer Registries and National Cancer Institute's Surveillance, Epidemiology, and End Results Program on cancer incidence in the United States population. The USCS report includes incidence data for 20 out of the 30 cancer types observed in our study population, including breast, ovarian, bladder, brain & CNS, cervical, colorectal, esophagus, Hodgkin lymphoma, non-Hodgkin lymphoma, kidney, leukemia, lung, melanoma, myeloma, oral cavity, ovarian, pancreas, prostate, stomach, thyroid, and uterine (USCS Working Group, 2013).
Cancers without general population incidence rates in the USCS database were excluded from analysis. The excluded cancer types were male breast cancer, eye/orbit, lower GI, lymphoma, osteosarcoma, sarcoma, skin/nonmelanoma, unknown primary site, upper GI, and vulvar. The defined reference time frame for age-specific incidence rates in USCS was 2006-2010.
Standardized incidence ratios (SIR) were calculated to compare number of cases of cancer in the sample population with general population data. The expected number of cancer cases was calculated from the number of individuals in the study sample multiplied by the general population cancer incidence rates. The expected and observed numbers of cases were calculated in 5 year intervals to accommodate different age-related incidence rates. SIRs for each cancer type, and associated confidence intervals (CIs), were calculated for the entire sample and for BRCA1 mutation carriers and BRCA2 mutation carriers separately. Data were also stratified by sex within the three groups. To account for multiple tests, we divided the standard p value of 0.05 for statistical significance by the number of cancer types; thus with 20 tests a p value of <0.0025 was considered statistically significant.
Results
We identified 1081 individuals with a deleterious mutation or variant suspected to be deleterious in BRCA1 or BRCA2 (Fig. 1) . We excluded 3 who had both BRCA1 and BRCA2 mutations, and 6 who had another genetic mutation or genetic condition in addition to a BRCA Comparison of the observed and expected cases identified four types of cancer with an increased SIR ( Table 2) . As expected, breast and ovarian cancers were observed at significantly increased rates in BRCA1 and BRCA2 mutation carriers. Individuals with a BRCA2 mutation had a higher incidence of pancreatic cancer than expected in the general population We observed a trend of increasing incidence of melanoma in BRCA1 mutation carriers (SIR 3.312, p=0.004 ) and of cervical cancer in BRCA2 mutation carriers (SIR 4.410, p=0.006 ), compared to general population data. The p values for melanoma and cervical cancer are approaching significance although they did not reach the conservative cutoff. The 95% confidence interval does not include 1.0 indicating that the general population and study sample are likely different populations. The increased incidence for these cancers was unlikely to occur by chance.
Ten additional cancer types representing 64 total cases were identified in the study population but were not available in the CDC USCS database for statistical analysis (Table 3) .
Individuals with BRCA1 mutations made up 45.3% (29 cases) in this subset of cancers.
Individuals with BRCA2 mutations comprised 54.7% (35 cases) in this subset of cancer types.
Of note, all seven cases of male breast cancer occurred in men with BRCA2 mutations. Nonmelanoma skin cancer was the most common of these 10 types of cancer in BRCA1 and BRCA2 mutation carriers (18 and 19 cases, respectively). 
Discussion
This is one of the largest single institution studies of the cancer spectrum associated with BRCA1 and BRCA2 mutations. This study found an increased incidence in two cancers, other than breast and ovarian, in individuals with a BRCA mutation when stratified by gene and sex. The number of observed cases of pancreatic and prostate cancer was higher than expected in the general population for individuals with BRCA2 mutations. Individuals with a BRCA1 mutation did not have an increased incidence of any specific type of cancer. Our findings support the rationale for pancreatic and prostate cancer screening in individuals with a BRCA2 mutation. Furthermore, recent associations with additional cancers, including uterine and colorectal, were not evident in our study population.
In our analysis, the occurrence of pancreatic cancer in males and females with a BRCA2 mutation was nearly 22 times greater than expected in the study population. Other studies have reported increased risks of a lesser magnitude for pancreatic cancer in men and women with BRCA2 mutations, including relative risk estimates ranging from 3.51-5.9 (BCLC, 1999; Moran et al., 2012; van Asperen et al., 2005) . The increased number of observed cases in this study above previous relative risks could be attributed to personal factors or a referral bias. Nearly half (8 of 19) individuals with pancreatic cancer had a history of smoking, which is a well documented risk factor for pancreatic cancer (Lowenfels & Maisonneuve, 2006) . MDACC is a tertiary care center and individuals with complex cancer histories, poor prognosis, or multiple cancer diagnoses are often referred for treatment. Of note, the SIR used in this study is not relative risk. The SIR is an approximation of the relative risk; however, discrepancies can arise because the general population is composed of individuals with and without BRCA mutations. Therefore, it is difficult to truly compare these statistical analyses.
Prostate cancer occurred approximately 5 times more frequently in males with BRCA2 mutations than expected in the general population. The increased risk for prostate cancer in our study population is consistent with previous studies that have reported relative risk estimates ranging from 2. 5-6.3 (BCLC, 1999; Easton et al., 1997; Moran et al., 2012; van Asperen et al., 2005) . Our data confirms prior evidence that men with BRCA2 mutations are at an increased risk of prostate cancer.
The incidence of melanoma in BRCA1 mutation carriers approached significance in this study (p = 0.004). We established a conservative level of statistical significance for this study because the study sample included individuals in multiple cancer groups rather than being mutually exclusive group comparisons. The 95% confidence interval suggests the increased incidence of melanoma in BRCA1 mutation carriers differentiates it from the general population.
Melanoma has been associated with BRCA2 mutations in previous studies, although the risk with BRCA1 mutations is unclear (BCLC, 1999) . Therefore this study suggests screening for melanoma in BRCA1 mutation carriers may be prudent.
The incidence of cervical cancer in BRCA2 mutation carriers also approached statistical significance in this study (p=0.006). The most common risk factor for cervical cancer is human papillomavirus infection (Schiffman et al., 2007) . We were unable to determine whether the cause of cervical cancer was viral or possibly associated with BRCA2 mutations. HPV status was available for three out of the six observed cervical cancer cases in women with a BRCA2 mutation. All three tested negative for HPV; however, the test was performed 3 to 7 years after cancer diagnosis. Thus the tests may not have accurately identified HPV because the majority of HPV infections clear or become undetectable within two years of infection (Moscicki et al., 1998) . HPV status was not reported in the medical record for the remaining three individuals. It will be important to monitor the cancers with a trend of increasing incidence over time to determine if an association exists and what the magnitude of risk is for mutation carriers.
BRCA mutations have been associated with uterine cancer risk, specifically more aggressive types (Shu et al., 2014) . Women in the study had a BRCA1 or BRCA2 mutation and underwent a BSO, and their uterus remained intact. Four cases of high-risk uterine cancer were diagnosed out of 525 women during the study, which was significantly increased over the general population (SIR 14.48, p<0.001) . In our overall sample, 7 cases of uterine cancer were observed compared to 5.507 expected. Three of the observed cases were classified as high risk (serous, clear cell, or sarcoma), three cases were low risk, and one case did not have pathology available for review. Thus, uterine cancer was not more prevalent in our study population than expected, although the occurrence of high risk uterine cancer was not specifically assessed.
Male breast cancer was not able to be analyzed in this study because of insufficient general population data for comparison. Of note, all seven cases were observed in men with BRCA2 mutations which represent 21% of the men with a mutation in this gene. Our results appear to be consistent with prior studies that have found a stronger association with BRCA2 mutations and male breast cancer compared to BRCA1 mutations (Tai et al., 2007) .
Although our overall sample size of individuals with BRCA mutations is large in comparison to other published studies, the sample size remains a limitation for discovering small differences. Therefore a larger sample size is needed to assess the statistical significance of rare cancer in association with BRCA mutations. This might be accomplished by analyzing family histories for additional cancer or by collaborating with another large center.
Another limitation is the use of general population incidence rates. The largest date range (2006) (2007) (2008) (2009) (2010) in the USCS dataset was used; however, individuals in our sample developed cancer outside of this date range which required us to infer statistical associations. Also, cancers diagnosed at centers other than ours did not require pathological confirmation; thus there may be inaccurate reporting for some cancers. Because our study population was predominantly white (75%), the information learned from this study may not be generalizable across all ethnicities.
Our study observed more than the expected number of cases of pancreatic and prostate cancer in BRCA2 mutation carriers. A trend toward statistical significance in the incidence of melanoma with BRCA1 mutations was observed. The presence of male breast cancer exclusively with BRCA2 mutation carriers is consistent with previous studies. These While the risk for pancreatic cancer has been acknowledged by NCCN, specific screening guidelines do not exist. Lack of effective procedures for early pancreatic cancer detection prevents the development of screening guidelines. The high rate of pancreatic cancer in men and women with BRCA2 mutations in this study further emphasizes the need for effective screening guidelines in this high-risk population.
